AR033965A1 - USE OF A TNFALFA ANTAGONIST, TO TREAT OR INHIBIT THE CELL INJURY OR DEATH OF THE CELLS - Google Patents

USE OF A TNFALFA ANTAGONIST, TO TREAT OR INHIBIT THE CELL INJURY OR DEATH OF THE CELLS

Info

Publication number
AR033965A1
AR033965A1 ARP010100604A ARP010100604A AR033965A1 AR 033965 A1 AR033965 A1 AR 033965A1 AR P010100604 A ARP010100604 A AR P010100604A AR P010100604 A ARP010100604 A AR P010100604A AR 033965 A1 AR033965 A1 AR 033965A1
Authority
AR
Argentina
Prior art keywords
tnfalfa
antagonist
death
cells
inhibit
Prior art date
Application number
ARP010100604A
Other languages
Spanish (es)
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of AR033965A1 publication Critical patent/AR033965A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Uso de antagonista TNFalfa para la elaboración de un medicamento para e tratamiento o inhibición de la lesión celular o la muerte de las células después de un evento isquémico, el tratamiento o inhibición de la lesión por reperfución y la reducción de la mortalidad posterior al infarto de miocardio.Use of TNFalfa antagonist for the preparation of a medicament for the treatment or inhibition of cell injury or the death of cells after an ischemic event, the treatment or inhibition of reperfusion injury and the reduction of mortality after infarction of myocardium

ARP010100604A 2000-02-10 2001-02-09 USE OF A TNFALFA ANTAGONIST, TO TREAT OR INHIBIT THE CELL INJURY OR DEATH OF THE CELLS AR033965A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US50186200A 2000-02-10 2000-02-10

Publications (1)

Publication Number Publication Date
AR033965A1 true AR033965A1 (en) 2004-01-21

Family

ID=23995312

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP010100604A AR033965A1 (en) 2000-02-10 2001-02-09 USE OF A TNFALFA ANTAGONIST, TO TREAT OR INHIBIT THE CELL INJURY OR DEATH OF THE CELLS

Country Status (9)

Country Link
EP (1) EP1261364A1 (en)
JP (1) JP2003522155A (en)
CN (1) CN1406132A (en)
AR (1) AR033965A1 (en)
AU (1) AU2001236764A1 (en)
BR (1) BR0108193A (en)
CA (1) CA2399436A1 (en)
MX (1) MXPA02007683A (en)
WO (1) WO2001058473A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2311094T3 (en) * 2002-02-27 2009-02-01 Immunex Corporation STABILIZED COMPOSITION OF TNFR-FC THAT INCLUDES ARGININA.
US9028822B2 (en) 2002-06-28 2015-05-12 Domantis Limited Antagonists against TNFR1 and methods of use therefor
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc Self-buffering protein formulations
US10485869B2 (en) 2011-10-18 2019-11-26 Coherus Biosciences, Inc. Etanercept formulations stabilized with meglumine
SG11201401562RA (en) 2011-10-18 2014-09-26 Coherus Biosciences Inc Etanercept formulations stabilized with sodium chloride
CN104661651A (en) 2012-07-09 2015-05-27 科荣生生物科学公司 Etanercept formulations exhibiting marked reduction in sub-visible particles
ES2657377T3 (en) 2012-09-11 2018-03-05 Coherus Biosciences, Inc. Etanercept folded correctly with high purity and excellent performance
JP6884858B2 (en) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド Pharmaceutical product and its manufacturing method

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1132471A3 (en) * 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-binding proteins
US7608262B2 (en) * 1996-02-16 2009-10-27 The Kennedy Institute Of Rheumatology Methods of preventing or treating thrombosis with tumor necrosis factor antagonists
AR016551A1 (en) * 1997-07-30 2001-07-25 Smithkline Beecham Corp DERIVATIVES OF 2-OXINDOL, PHARMACEUTICAL COMPOSITIONS THAT INCLUDE THEM AND THE USE OF THE SAME FOR THE MANUFACTURE OF MEDICINES
NL1007890C2 (en) * 1997-12-24 1999-07-12 Dutch Trading Dutra B V Assembly of a rail system, at least one piece of cloth and a number of fastening elements for fixing the cloth to the rail system.
FR2779724B1 (en) * 1998-06-10 2001-04-20 Rhone Poulenc Rorer Sa PYRROLE DERIVATIVES, THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
WO2000062790A2 (en) * 1999-04-19 2000-10-26 Immunex Corporation Soluble tumor necrosis factor receptor treatment of medical disorders

Also Published As

Publication number Publication date
AU2001236764A1 (en) 2001-08-20
BR0108193A (en) 2003-02-25
JP2003522155A (en) 2003-07-22
EP1261364A1 (en) 2002-12-04
WO2001058473A1 (en) 2001-08-16
MXPA02007683A (en) 2002-12-13
CN1406132A (en) 2003-03-26
CA2399436A1 (en) 2001-08-16

Similar Documents

Publication Publication Date Title
CU23423B7 (en) OXAZOLIDINONES REPLACED AND ITS USE IN THE FIELD OF BLOOD COAGULATION
CO5271710A1 (en) COMBINANCES OF A THYROSINE KINASE INHIBITOR RECEPTORA WITH AN ORGANIC COMPOSITE ABLE TO LINK WITH ACID-A GLYCORPOTHINE
BR0316234A (en) Hydroxyindols, their use as phosphodiesterase 4 inhibitors and processes for their preparation
AR023966A1 (en) A PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND / OR TREATMENT OF PARKINSON'S DISEASE AND THE CONCOMITING SYMPTOMS OF THE SAME, AND THE USE OF A DUAL ADENOSINE A1 A2A RECEIVER UNANTAGONIST TO PREPARE SUCH COMPOSITION
BR9710801A (en) Purine kinase 2 inhibitors dependent on decycline and ikb-a
FI953748A (en) Compounds with both potent calcium antagonist and antioxidant activity and their use as cell protective agents
ECSP034773A (en) PIRAZOLOPIRIMMIDINAS AS THERAPEUTIC AGENTS
ECSP055840A (en) DERIVATIVES OF 4-TETRAZOLIL-4 PHENYLPIPERIDINE FOR THE TREATMENT OF PAIN
BRPI0408858A (en) use of an ibat inhibitor or a pharmaceutically acceptable salt, solvate, solvate of such a salt or a prodrug thereof, pharmaceutical composition, and method of treatment and / or prophylaxis of constipation in a warm-blooded animal
AR023078A1 (en) AN ARTICLE FOR PERSONAL HYGIENE INHIBITING THE SKIN IRRITATION AND A METHOD FOR SEQUENCING SKIN IRRITANTS
EA200200207A1 (en) APPLICATION OF CGRP ANTAGONISTS AND CGRP RELIEF INHIBITORS TO ELIMINATE TIDES IN THE PERIOD OF MENOPAUSE
AR033965A1 (en) USE OF A TNFALFA ANTAGONIST, TO TREAT OR INHIBIT THE CELL INJURY OR DEATH OF THE CELLS
AR018162A1 (en) SUBSTITUTED PIRROLS, PHARMACEUTICAL COMPOSITION AND THE USE OF THEM FOR THE PREPARATION OF SUCH PHARMACEUTICAL COMPOSITION
AR031601A1 (en) DERIVATIVES OF 4-PYRIMIDINAMINE, PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS
HUP0200152A2 (en) Utilization of inhibitors of the kqt1 channel in order to produce a medicament for treating diseases which are caused by parasitic helminths and ectoparasites
AR032422A1 (en) USE OF IL-18 INHIBITORS FOR THE TREATMENT AND / OR PREVENTION OF CARDIAC DISEASE
PA8525801A1 (en) PIRAZOL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS TO MODULATE AND / OR INHIBIT THE ACTIVITY OF ERAB / HADH2
PA8618401A1 (en) PREVENTION AND TREATMENT OF HYPERTENSIVE CARDIAC DISEASES THROUGH THE USE OF SELECTIVE STROGENS 8BETA-VINIL-ESTRA-1,3,5 (10) -TRIEN-3,17BETA-DIOL AND 17BETA-FLUOR-9ALFA-VINIL-ESTRA-1.3,5 (10) -TRIEN-3.16ALFA-DIOL
AR035600A1 (en) USE OF SELECTIVE AGONISTS OF DOPAMINE D4 RECEPTOR IN THE MANUFACTURE OF MEDICINES TO TREAT SEXUAL DYSFUNCTION
PE20000701A1 (en) COMBINATION OF FENTHOLAMINE AND APOMORPHINE FOR THE TREATMENT OF HUMAN SEXUAL FUNCTION AND DYSFUNCTION
DK1015437T3 (en) Benzoxazine and benzothiazine derivatives and their use in pharmaceuticals
UY26648A1 (en) VASOPEPTIDASE INHIBITORS TO TREAT ISOLATED SYSTOLIC HYPERTENSION
UY26307A1 (en) EFFICIENT SYNTHETIC ROUTES FOR THE PREPARATION OF RHINOVIRUS PROTEASE INHIBITORS AND KEY INTERMEDIATES
CO5271686A1 (en) NEW USE OF (R) - (-) - 2- [5- (4-FLUROPHENYL) -3-PYRIDYLMETHYL-AMYNOMETIL] -CROMANO AND ITS ACCEPTABLE SALTS FOR PHYSIOLOGICAL USE
PE20020511A1 (en) USE OF ANTIPROGESTINES FOR THE INDUCTION OF APOPTOSIS IN A CELL

Legal Events

Date Code Title Description
FA Abandonment or withdrawal